# Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

> **NCT06682169** · PHASE3 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 182 (estimated)

## Conditions studied

- Graft-versus-host Disease

## Interventions

- **DRUG:** Rovadicitinib
- **DRUG:** Imatinib
- **DRUG:** Methotrexate
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06682169
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2029-10
- **Final completion:** 2030-12
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06682169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06682169, "Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06682169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*